Dear Subscriber,
2019 has already been busy and we are coming up on some important conferences. At the end of March, we will present multiple abstracts at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta from March 29 to April 3, 2019. Simultaneously, data contributed by Biognosys will be presented by Roche at the US meeting for Mass Spectrometry: Applications to the Clinical Lab (MSACL) Annual Conference, which highlights the implementation of a discovery proteomics pipeline that can be applied to support clinical research programs.
BIOGNOSYS TO PRESENT MULTIPLE WORKFLOWS AT AACR 2019
At AACR, Biognosys will be presenting abstracts that highlight multiple new applications which are enabled by the HRM™-MS platform. Dr. Nigel Beaton will present new data for our drug target identification service (LiP-MS), which is based on limited proteolysis coupled with HRM™-MS. In this work targets of both specific and broad kinase inhibitors (selumetinib and staurosporine) were identified and LiP peptides were successfully mapped to known ATP binding sites. This work will be followed by poster presentations highlighting our workflows for unbiased phospho-proteomic analysis, which is used to refine cancer pathway modeling, and high-dimensional proteomic phenotyping of primary immune cell subsets to characterize the processes driving immune cell activation and suppression.
Presentation details are as follows:
Presentation: “Limited Proteolysis Coupled to Mass Spectrometry (LiP-MS), a Novel Drug Target Deconvolution Strategy”
Abstract Number: 2755
Session: Cancer Chemical Biology and Therapeutics Development
Date and Time: Tuesday, April 2, 8:00 AM – 12:00 PM
Presentation: “Unbiased Phospho-Proteomic Profiling of Mouse Breast Cancer Models with DIA Mass Spectrometry Refines CanPath Prototype, a Platform for Predictive Cancer Pathway Modeling”
Abstract Number: 3916
Session: PI3k/AKT Inhibitors
Date and Time: Tuesday, April 2, 1:00 PM – 5:00 PM
Presentation: “High Dimensional Proteomic Profiling of Immune Cell Subsets with Data Independent Acquisition Mass Spectrometry”
Abstract Number: 4547
Session: Immune Cells in the Tumor Microenvironment 3
Date and Time: Wednesday, April 3, 8:00 AM – 12:00 PM
BIOGNOSYS DATA TO BE PRESENTED BY DR. AXEL DUCRET FROM ROCHE AT MSACL 2019 US HIGHLIGHTING THE IMPLEMENTATION OF DISCOVERY PROTEOMICS FOR CLINICAL INVESTIGATIONS
While discovery proteomics is currently used primarily in a research environment, Dr. Axel Ducret, Principal Scientist - Project Leader at F. Hoffman-La Roche, will present data contributed by Biognosys to a mock study to implement discovery proteomics in a clinical investigation framework. For this study, a representative set of 30 FFPE colorectal cancer (CRC) tumor specimens were analyzed with Biognosys’ DIA LC-MS/MS platform. Across all samples, nearly 9,000 proteins were quantified with a very low technical variance of 5% median %CV. The results of this study lay the foundation for a discovery proteomics pipeline that can be operated and documented according to GCP guideline and therefore applied to support clinical trial investigations.
Presentation: “Clinical Proteomics Enters Clinical Trials: A Generic GCP-compliant Workflow for the Routine Analysis of FFPE Tissue Samples by Quantitative Mass Spectrometry”
Abstract Number: 782
Session: Proteomics: Discovery/Translation II
Date and Time: Wednesday, April 3, 11:00 AM
MEET OUR TEAM AT THESE UPCOMING CONFERENCES
AACR Annual Meeting
March 29-April 2, 2019, Atlanta, GA, USA
MSACL - Mass Spectrometry: Applications to the Clinical Lab
March 31-April 4, 2019, Palm Springs, CA, USA
Keystone Symposium on Proteomics and its Application to
Translational and Precision Medicine
April 7-11, 2019, Stockholm, Sweden
ASGCT Annual Meeting
April 29-May 2, 2019, Washington DC, USA
Best,
- The Biognosys Team
